Pharvaris (NASDAQ:PHVS) Sets New 1-Year Low – Time to Sell?

Pharvaris (NASDAQ:PHVS) shares hit a new 52-week low during mid-day trading on Thursday . The stock traded as low as $14.50 and last traded at $14.99, with a volume of 152659 shares. The stock had previously closed at $15.45.

Wall Street Analysts Forecast Growth

Separately, JMP Securities raised their target price on shares of Pharvaris from $46.00 to $55.00 and gave the company a “market outperform” rating in a report on Friday, January 31st.

Pharvaris Trading Down 3.0 %

The stock has a market cap of $783.83 million, a P/E ratio of -5.35 and a beta of -3.02. The company has a 50-day moving average price of $17.57 and a two-hundred day moving average price of $19.24.

Institutional Investors Weigh In On Pharvaris

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Public Employees Retirement System of Ohio purchased a new position in shares of Pharvaris during the 3rd quarter worth about $57,000. JPMorgan Chase & Co. boosted its position in shares of Pharvaris by 1,125.3% during the fourth quarter. JPMorgan Chase & Co. now owns 3,100 shares of the company’s stock valued at $59,000 after buying an additional 2,847 shares during the period. Cubist Systematic Strategies LLC bought a new position in shares of Pharvaris during the fourth quarter valued at approximately $64,000. Barclays PLC purchased a new stake in shares of Pharvaris in the third quarter worth approximately $106,000. Finally, KLP Kapitalforvaltning AS purchased a new position in Pharvaris during the 4th quarter valued at $111,000.

Pharvaris Company Profile

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.